Last reviewed · How we verify
rosiglitazone (4 mg)/day
Rosiglitazone activates PPAR-γ, leading to increased insulin sensitivity and glucose uptake in adipose tissue.
Rosiglitazone activates PPAR-γ, leading to increased insulin sensitivity and glucose uptake in adipose tissue. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | rosiglitazone (4 mg)/day |
|---|---|
| Sponsor | National Cheng-Kung University Hospital |
| Drug class | Thiazolidinedione |
| Target | PPAR-γ |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Activation of PPAR-γ by rosiglitazone results in the transcriptional regulation of genes involved in glucose and lipid metabolism. This leads to increased insulin sensitivity and glucose uptake in adipose tissue, as well as decreased glucose production in the liver.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Fluid retention
- Weight gain
- Edema
- Headache
- Nausea
Key clinical trials
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Rosiglitazone in Treating Patients With Liposarcoma (PHASE2)
- Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome (NA)
- Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease (PHASE2)
- Rosiglitazone in Treating Patients With Pituitary Tumors (PHASE2)
- Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients. (PHASE2, PHASE3)
- Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes (PHASE3)
- Preferred Treatment of Type 1.5 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rosiglitazone (4 mg)/day CI brief — competitive landscape report
- rosiglitazone (4 mg)/day updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI